Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 26, 2024
When we launched Pandemic Proof, many countries were still in the throes of the health and economic shocks of COVID-19. Lessons learned from the pandemic were still fresh. And the visibility and urgency of the pandemic catalyzed some important policy action, including the establishment of innovative...
Blog Post
January 10, 2024
This blog outlines key considerations regarding how the AEF raises and spends funds, underscoring the significance of a robust design and effective implementation at a time when the AEF’s proposed governance and operational mechanisms are being deliberated on and presented to the AU policy organs fo...
POLICY PAPERS
June 20, 2023
This policy paper examines the state of knowledge on investing in the “best buys” of surveillance for pandemic preparedness. We conduct a rapid literature review to assess the state of knowledge on the costs and benefits of investing in four selected types of surveillance for respiratory infections,...
Blog Post
May 02, 2023
The investment case for bolstering global systems for pandemic preparedness and response is clear. Yet, COVID-19 exposed gaping holes in our collective ability to respond to pandemic threats. And even after more than 6.9 million deaths from COVID-19 and trillions in economic losses, financing and po...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Blog Post
February 23, 2023
How can we ensure that medical countermeasures—such as diagnostics and vaccines—are ready to go at local, national, and global levels when the next pandemic emerges? Amanda Glassman speaks with Dr. Amadou Alpha Sall of Institut Pasteur of Dakar and Dr. Rachel Glennerster of the University of Chicago...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.